Illana Gozes

Summary

Publications

  1. ncbi NAP (davunetide) provides functional and structural neuroprotection
    Illana Gozes
    The Adams Super Center for Brain Studies, Israel
    Curr Pharm Des 17:1040-4. 2011
  2. ncbi Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Pharm Des 17:2603-12. 2011
  3. doi NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia
    Avia Merenlender-Wagner
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 31:1368-73. 2010
  4. doi Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model
    Anat Idan-Feldman
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Neurobiol Dis 44:327-39. 2011
  5. doi 3R tau expression modifies behavior in transgenic mice
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, and the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Neurosci Res 88:2727-35. 2010
  6. pmc The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities
    Saar Oz
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e51458. 2012
  7. ncbi Addressing Alzheimer's disease tangles: from NAP to AL-108
    Illana Gozes
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Levi Edersheim Gitter Institute for Functional Brain Imaging, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 6:455-60. 2009
  8. pmc Tau and caspase 3 as targets for neuroprotection
    Anat Idan-Feldman
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Molecular Neuroendocrinology, and Department of Human Molecular Genetics and Biochemistry, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Int J Alzheimers Dis 2012:493670. 2012
  9. doi NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel
    Neurobiol Dis 34:381-8. 2009

Collaborators

  • Hanna Rosenmann
  • Natalia Shiryaev
  • Anat Idan-Feldman
  • Eliezer Giladi
  • Saar Oz
  • Regina Pikman
  • Avia Merenlender-Wagner
  • Nikolaos C Grigoriadis
  • Eleni Polyzoidou
  • Yan Jouroukhin
  • Yanina Ivashko-Pachima
  • Regina Ostritsky
  • Yulie Schirer
  • Olga Touloumi
  • Roza Lagoudaki
  • Annie Andrieux

Detail Information

Publications9

  1. ncbi NAP (davunetide) provides functional and structural neuroprotection
    Illana Gozes
    The Adams Super Center for Brain Studies, Israel
    Curr Pharm Des 17:1040-4. 2011
    ..The interaction of these disparate yet complementary pathways is the subject of future studies toward human brain neuroprotection in the clinical scenario...
  2. ncbi Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Pharm Des 17:2603-12. 2011
    ..These studies associate neuroprotection in vivo and in vitro and provide a broad base for future drug development based on NAP and D-SAL against multiple neurodegenerative conditions...
  3. doi NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia
    Avia Merenlender-Wagner
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 31:1368-73. 2010
    ..Daily intranasal NAP treatment significantly decreased hyperactivity in the STOP+/- mice and protected visual memory...
  4. doi Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model
    Anat Idan-Feldman
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Neurobiol Dis 44:327-39. 2011
    ..NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to prevent diabetes-related brain pathologies in the streptozotocin injected diabetes rat model...
  5. doi 3R tau expression modifies behavior in transgenic mice
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, and the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Neurosci Res 88:2727-35. 2010
    ..In conclusion, 7-8-month-old tau-tg mice overexpressing nonmutated 0N3R human tau isoform demonstrated enhanced behavior in the passive avoidance test, paralleled by relative tau hypophosphorylation in the subcortical brain region...
  6. pmc The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities
    Saar Oz
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e51458. 2012
    ..NAP (davunetide) is in phase 2/3 clinical trial in progressive supranuclear palsy, a disease presenting MT deficiency and tau pathology...
  7. ncbi Addressing Alzheimer's disease tangles: from NAP to AL-108
    Illana Gozes
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Levi Edersheim Gitter Institute for Functional Brain Imaging, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 6:455-60. 2009
    ..The following article reviews NAP's discovery and pharmacological characterization that has led to clinical development of a novel tangle-directed drug candidate...
  8. pmc Tau and caspase 3 as targets for neuroprotection
    Anat Idan-Feldman
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Molecular Neuroendocrinology, and Department of Human Molecular Genetics and Biochemistry, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Int J Alzheimers Dis 2012:493670. 2012
    ..Our data suggest that, in this model system, caspase activation may be an upstream event to tau hyperphosphorylation, although additional studies will be required to fully elucidate the cascade of events...
  9. doi NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel
    Neurobiol Dis 34:381-8. 2009
    ..The current studies show for the first time activity for NAP in a "pure" tauopathy model, positioning it as a promising drug candidate in multiple neurodegenerative tauopathies...